Product Description: Anumigilimab (CSL-324) is an human IgG2a mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Markota Čagalj A, et al. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022 Mar 29;23(7):3753. /[2]Rosales Santillan M, et al. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2020 Jun;20(6):621-633.